WO2009138601A3 - Utilisation de derives de mannose-6-phosphate pour le controle de l 'angiogenese et la regeneration ligamentaire et la reconstruction de cartilage - Google Patents

Utilisation de derives de mannose-6-phosphate pour le controle de l 'angiogenese et la regeneration ligamentaire et la reconstruction de cartilage Download PDF

Info

Publication number
WO2009138601A3
WO2009138601A3 PCT/FR2009/000525 FR2009000525W WO2009138601A3 WO 2009138601 A3 WO2009138601 A3 WO 2009138601A3 FR 2009000525 W FR2009000525 W FR 2009000525W WO 2009138601 A3 WO2009138601 A3 WO 2009138601A3
Authority
WO
WIPO (PCT)
Prior art keywords
mannose
phosphate
ligament regeneration
cartilage reconstruction
controlling angiogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2009/000525
Other languages
English (en)
Other versions
WO2009138601A2 (fr
Inventor
Jean-Louis Montero
Véronique MONTERO
Jean-Pierre Moles
Pascal De Santa Barbara
Caroline Clavel
Bernard Jover
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to CA2723768A priority Critical patent/CA2723768A1/fr
Priority to EP09745920A priority patent/EP2280985A2/fr
Priority to JP2011507963A priority patent/JP2011520803A/ja
Priority to US12/991,631 priority patent/US20110112044A1/en
Publication of WO2009138601A2 publication Critical patent/WO2009138601A2/fr
Publication of WO2009138601A3 publication Critical patent/WO2009138601A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C07H11/04—Phosphates; Phosphites; Polyphosphates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02—Acyclic radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La présente invention est relative à l'utilisation du mannose-6-phosphate (M6P) et de certains de ses dérivés pour le contrôle de l'angiogenèse et la régénération ligamentaire et/ou la reconstruction de cartilage. Le M6P et certains de ses dérivés peuvent notamment être utilisés pour la préparation d'une composition pharmaceutique destinée à la régénération ligamentaire et/ou la reconstruction de cartilages.
PCT/FR2009/000525 2008-05-07 2009-05-05 Nouvelles utilisations de derives de d-mannopyranose Ceased WO2009138601A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA2723768A CA2723768A1 (fr) 2008-05-07 2009-05-05 Nouvelles utilisations de derives de d-mannopyranose
EP09745920A EP2280985A2 (fr) 2008-05-07 2009-05-05 Utilisation de derives de mannose-6-phosphate pour le contrôle de l'angiogénèse et la regénération ligamentaire et la reconstruction de cartilage
JP2011507963A JP2011520803A (ja) 2008-05-07 2009-05-05 Ｄ−マンノピラノース誘導体
US12/991,631 US20110112044A1 (en) 2008-05-07 2009-05-05 Novel uses of d-mannopyranose derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0802537 2008-05-07
FR0802537A FR2930943B1 (fr) 2008-05-07 2008-05-07 Nouvelles utilisations de derives de d-mannopyranose inhibiteurs de l'angiogenese

Publications (2)

Publication Number Publication Date
WO2009138601A2 WO2009138601A2 (fr) 2009-11-19
WO2009138601A3 true WO2009138601A3 (fr) 2010-03-04

Family

ID=40336799

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2009/000525 Ceased WO2009138601A2 (fr) 2008-05-07 2009-05-05 Nouvelles utilisations de derives de d-mannopyranose

Country Status (6)

Country Link
US (1) US20110112044A1 (fr)
EP (1) EP2280985A2 (fr)
JP (1) JP2011520803A (fr)
CA (1) CA2723768A1 (fr)
FR (1) FR2930943B1 (fr)
WO (1) WO2009138601A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2424542A4 (fr) * 2009-04-28 2012-12-19 Pharmaxis Ltd Composés phosphotétrahydropyrane pour le traitement de lésions et de troubles de type « fibreux »
CN103601767B (zh) * 2013-11-03 2016-06-29 大连九信生物化工科技有限公司 一种4,6-二羟基保护的葡萄吡喃己糖衍生物的脱保护方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0527042A2 (fr) * 1991-08-06 1993-02-10 PHARMACIA S.p.A. Dérivés de 3-deoxymannosamine et procédé pour leur préparation
WO2006002332A1 (fr) * 2004-06-23 2006-01-05 Angiotech Biomaterials Corporation Reparation des cartilages: methodes et compositions polymeres reticulees
US20080057072A1 (en) * 2006-08-31 2008-03-06 Alcon Manufacturing, Ltd. Antagonists of ci-m6p/igf2r for prevention and treatment of ctgf-mediated ocular disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0527042A2 (fr) * 1991-08-06 1993-02-10 PHARMACIA S.p.A. Dérivés de 3-deoxymannosamine et procédé pour leur préparation
WO2006002332A1 (fr) * 2004-06-23 2006-01-05 Angiotech Biomaterials Corporation Reparation des cartilages: methodes et compositions polymeres reticulees
US20080057072A1 (en) * 2006-08-31 2008-03-06 Alcon Manufacturing, Ltd. Antagonists of ci-m6p/igf2r for prevention and treatment of ctgf-mediated ocular disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
COCHRAN, SISKA ET AL: "Probing the interactions of phosphosulfomannans with angiogenic growth factors by surface plasmon resonance", JOURNAL OF MEDICINAL CHEMISTRY , 46(21), 4601-4608 CODEN: JMCMAR; ISSN: 0022-2623, 2003, XP002514918 *
FAIRWEATHER J K ET AL: "The synthesis of phosphorylated disaccharide components of the extracellular phosphomannan of Pichia (Hansenula) holstii NRRL Y-2448", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 12, no. 23, 1 December 2004 (2004-12-01), pages 6063 - 6075, XP004615080, ISSN: 0968-0896 *
GERBER H-P ET AL: "VEGF COUPLES HYPERTROPHIC CARTILAGE REMODELING, OSSIFICATION AND ANGIOGENESIS DURING ENDOCHONDRAL BONE FORMATION", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 5, no. 6, 1 June 1999 (1999-06-01), pages 623 - 628, XP002909369, ISSN: 1078-8956 *
VOLPERT, OLGA ET AL: "The insulin-like growth factor II/ Mannose 6-phosphate receptor is required for proliferin-induced angiogenesis", ENDOCRINOLOGY , 137(9), 3871-3876 CODEN: ENDOAO; ISSN: 0013-7227, 1996, XP002514920 *

Also Published As

Publication number Publication date
CA2723768A1 (fr) 2009-11-19
WO2009138601A2 (fr) 2009-11-19
FR2930943A1 (fr) 2009-11-13
US20110112044A1 (en) 2011-05-12
FR2930943B1 (fr) 2011-03-18
JP2011520803A (ja) 2011-07-21
EP2280985A2 (fr) 2011-02-09

Similar Documents

Publication Publication Date Title
WO2010069532A8 (fr) Anticorps dirigés contre l'angiopoïétine 2 humaine
AP2012006191A0 (en) Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same.
IL209593A (en) Diamino-Pyridine, Pyrimidine and Pyridazine Derivatives, Pharmaceutical Preparations Containing Them and Uses as Modulators of Histamine H4 Receptor
WO2010048358A3 (fr) Inhibiteurs à base d'éthoxyphénylméthyle de sglt2
WO2008152099A3 (fr) Aryl/hétarylamides en tant que modulateurs du récepteur ep2
WO2011041694A3 (fr) Composés utiles comme antagonistes du récepteur de l'acide lysophosphatidique (lpa)
WO2011017350A3 (fr) Composés en tant qu'antagonistes du récepteur de l'acide lysophosphatidique
WO2010038238A3 (fr) Compositions de fibres diététiques
SI2107055T1 (sl) Derivati diosmetina, postopek za njihovo pripravo in njihovi farmacevtski sestavki
IL213570A (en) History 8 - Alkoxy - s - Triazolo [5,1 - a] pyridine and pharmaceutical preparations containing them
WO2008017346A3 (fr) Utilisation de dérivés d'acide ascorbique pour la fonctionnalisation de matrices
WO2009089234A3 (fr) Dibenzhydrylpipérazines substituées
WO2010147830A3 (fr) Modulateurs aminothiazole de bêta-3-adrénorécepteur
IN2012DN02793A (fr)
WO2011060363A3 (fr) Modulateurs des récepteurs d2 et/ou des récepteurs d3 à base de cyclohexylurée
WO2009115084A3 (fr) Nouveaux dérivés de pyrrolopyrimidine et leurs utilisations
WO2010049449A3 (fr) Nouveaux sels de sunitinib
SI2231598T1 (sl) Novi derivati diazeniumdiolata postopek pripravele teh in njihovi farmacevtski sestavki
WO2009154739A3 (fr) Modulateurs du récepteur smoothened
WO2011014520A3 (fr) Composés et compositions pouvant servir de modulateurs de l'activité du gpr119
WO2010042212A3 (fr) Méthodes de traitement prophylactique ou thérapeutique de la douleur à l'aide de dérivés de spicamycine
MX2011006721A (es) Formulacion farmaceutica de fenofibrato nanonizado.
WO2009124733A8 (fr) Dérivés de sulfonamide substitués
ZA201201715B (en) Process for the preparation of (1s,4r)-2-oxa-3-azabicyclo{[2,2.1]hept-5-enes
WO2010118286A3 (fr) Modulateurs de l'activité des récepteurs h1 et/ou de la protéine ns4b à base de benzimidazole

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2011507963

Country of ref document: JP

Ref document number: 2723768

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009745920

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12991631

Country of ref document: US